Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93


The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations.

Kattula S, Bagoly Z, Klára Tóth N, Muszbek L, Wolberg AS.

J Thromb Haemost. 2020 Jan 27. doi: 10.1111/jth.14744. [Epub ahead of print]


Factor XIII deficiency does not prevent FeCl3-induced carotid artery thrombus formation in mice.

Tang Z, Kattula S, Holle LA, Cooley BC, Lin FC, Wolberg AS.

Res Pract Thromb Haemost. 2019 Nov 6;4(1):111-116. doi: 10.1002/rth2.12278. eCollection 2020 Jan.


Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor.

Grover SP, Schmedes CM, Auriemma AC, Butler E, Parrish ML, Miszta A, Cleuren AC, Visser M, Heitmeier S, Posma JJ, Spronk HM, Antoniak S, Wolberg AS, Pawlinski R, Gailani D, Mackman N.

Blood Adv. 2020 Jan 14;4(1):207-216. doi: 10.1182/bloodadvances.2019000921.


The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex.

Singh S, Nazabal A, Kaniyappan S, Pellequer JL, Wolberg AS, Imhof D, Oldenburg J, Biswas A.

Biomolecules. 2019 Nov 21;9(12). pii: E765. doi: 10.3390/biom9120765.


Mechanistic rationale for factor XIII cotreatment in haemophilia.

Beckman JD, Wolberg AS.

Haemophilia. 2019 Nov;25(6):e377-e378. doi: 10.1111/hae.13855. Epub 2019 Oct 2. No abstract available.


Mice, men, and differences therein.

Wolberg AS.

J Thromb Haemost. 2019 Sep;17(9):1440-1442. doi: 10.1111/jth.14572. No abstract available.


Direct Amplification of Tissue Factor:Factor VIIa Procoagulant Activity by Bile Acids Drives Intrahepatic Coagulation.

Baker KS, Kopec AK, Pant A, Poole LG, Cline-Fedewa H, Ivkovich D, Olyaee M, Woolbright BL, Miszta A, Jaeschke H, Wolberg AS, Luyendyk JP.

Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2038-2048. doi: 10.1161/ATVBAHA.119.313215. Epub 2019 Aug 15.


Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause.

Hofer S, Ay C, Rejtö J, Wolberg AS, Haslacher H, Koder S, Pabinger I, Gebhart J.

J Thromb Haemost. 2019 Sep;17(9):1478-1488. doi: 10.1111/jth.14529. Epub 2019 Jul 15.


Fibrinogen and fibrin: An illustrated review.

Pieters M, Wolberg AS.

Res Pract Thromb Haemost. 2019 Mar 4;3(2):161-172. doi: 10.1002/rth2.12191. eCollection 2019 Apr. Review.


Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.

Faes C, Ilich A, Sotiaux A, Sparkenbaugh EM, Henderson MW, Buczek L, Beckman JD, Ellsworth P, Noubouossie DF, Bhoopat L, Piegore M, Renoux C, Bergmeier W, Park Y, Ataga KI, Cooley B, Wolberg AS, Key NS, Pawlinski R.

Blood. 2019 Jun 6;133(23):2529-2541. doi: 10.1182/blood.2019000424. Epub 2019 Apr 5.


Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1.

McCann JV, Xiao L, Kim DJ, Khan OF, Kowalski PS, Anderson DG, Pecot CV, Azam SH, Parker JS, Tsai YS, Wolberg AS, Turner SD, Tatsumi K, Mackman N, Dudley AC.

J Clin Invest. 2019 Mar 11;130:1654-1670. doi: 10.1172/JCI123106. eCollection 2019 Mar 11.


Coagulation Factor XIIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function.

Bäuml CA, Schmitz T, Paul George AA, Sudarsanam M, Hardes K, Steinmetzer T, Holle LA, Wolberg AS, Pötzsch B, Oldenburg J, Biswas A, Imhof D.

J Med Chem. 2019 Apr 11;62(7):3513-3523. doi: 10.1021/acs.jmedchem.8b01982. Epub 2019 Mar 21.


Coagulation factor XIIIa cross-links amyloid β into dimers and oligomers and to blood proteins.

Hur WS, Mazinani N, Lu XJD, Yefet LS, Byrnes JR, Ho L, Yeon JH, Filipenko S, Wolberg AS, Jefferies WA, Kastrup CJ.

J Biol Chem. 2019 Jan 11;294(2):390-396. doi: 10.1074/jbc.RA118.005352. Epub 2018 Nov 8.


Identification and characterization of novel mutations implicated in congenital fibrinogen disorders.

Smith N, Bornikova L, Noetzli L, Guglielmone H, Minoldo S, Backos DS, Jacobson L, Thornburg CD, Escobar M, White-Adams TC, Wolberg AS, Manco-Johnson M, Di Paola J.

Res Pract Thromb Haemost. 2018 Jul 2;2(4):800-811. doi: 10.1002/rth2.12127. eCollection 2018 Oct.


Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors.

Beckman JD, Kasthuri RS, Wolberg AS, Ma AD.

Haemophilia. 2018 Nov;24(6):e417-e420. doi: 10.1111/hae.13603. Epub 2018 Aug 24. No abstract available.


State of the art in factor XIII laboratory assessment.

Durda MA, Wolberg AS, Kerlin BA.

Transfus Apher Sci. 2018 Dec;57(6):700-704. doi: 10.1016/j.transci.2018.07.006. Epub 2018 Aug 4. Review.


Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.

Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.

Res Pract Thromb Haemost. 2018 Apr 12;2(3):407-428. doi: 10.1002/rth2.12095. eCollection 2018 Jul. Review.


Illustrated review article: A new format for disseminating scientific progress.

Wolberg AS, Cushman M.

Res Pract Thromb Haemost. 2018 Jun 10;2(3):405-406. doi: 10.1002/rth2.12124. eCollection 2018 Jul. No abstract available.


Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition.

Wolberg AS.

Curr Opin Hematol. 2018 Sep;25(5):358-364. doi: 10.1097/MOH.0000000000000445. Review.


Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.

Porrello A, Leslie PL, Harrison EB, Gorentla BK, Kattula S, Ghosh SK, Azam SH, Holtzhausen A, Chao YL, Hayward MC, Waugh TA, Bae S, Godfrey V, Randell SH, Oderup C, Makowski L, Weiss J, Wilkerson MD, Hayes DN, Earp HS, Baldwin AS, Wolberg AS, Pecot CV.

Nat Commun. 2018 May 18;9(1):1988. doi: 10.1038/s41467-018-04355-w.

Supplemental Content

Loading ...
Support Center